Rubén F. Á.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
- Phase 3 Study of Acalabrutinib with R-CHOP in Patients Aged ≤75 with Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
- Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of Ibrutinib and Rituximab in Treatment-naïve Follicular Lymphoma Patients
Data & Insights
Has run more than one trial at 89 of 260 partner sites.
Specializations
Multiple Myeloma and Plasma Cell Dyscrasias
Clinical research activity is centered on multiple myeloma, including newly diagnosed, relapsed/refractory, transplant-eligible, and transplant-ineligible disease, as well as precursor and related plasma cell conditions.
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Systemic light chain amyloidosis
- Monoclonal gammopathy of undetermined significance
- Smoldering multiple myeloma
The therapeutic focus includes immunotherapy, antibody-based treatments, and combination strategies for plasma cell disorders.
B-Cell Malignancies and Lymphoma
Research involvement extends to aggressive and indolent lymphoid malignancies, with attention to both frontline and relapsed settings.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma
- Mantle cell lymphoma
- Relapsed/refractory B-cell malignancies
Areas of interest include CD20-directed therapy, B-cell receptor pathway targeting, and novel immunologic approaches in lymphoma care.
Inflammatory Bowel Disease and Gastrointestinal Immunology
The investigator is active in trials for ulcerative colitis and Crohn’s disease, covering moderate to severe inflammatory disease and long-term disease control.
- Ulcerative colitis
- Crohn’s disease
- Histologic and clinical remission
- Maintenance therapy
- Obesity or overweight in inflammatory bowel disease
Therapeutic interests include interleukin-targeted therapy, gut-selective immunomodulation, and combined management of intestinal inflammation with metabolic disease.
Cardiovascular Disease, Thrombosis, and Lipid Disorders
Clinical work also covers atherosclerotic cardiovascular disease, acute coronary syndromes, bleeding-risk coronary interventions, and prevention of recurrent vascular events.
- Acute coronary syndrome
- Coronary artery disease
- Spontaneous coronary artery dissection
- Elevated lipoprotein(a)
- Chronic kidney disease with cardiovascular risk
Additional focus includes antiplatelet management, anticoagulation, and emerging strategies for cardiovascular risk reduction.
AL Amyloidosis and Cardiorenal Complications
Research interests include advanced AL amyloidosis with cardiac involvement, especially disease subsets associated with high cardiovascular burden.
- Stage IIIa cardiac AL amyloidosis
- Stage IIIb cardiac AL amyloidosis
- Relapsed/refractory systemic light chain amyloidosis
- Cardiovascular hospitalization risk
- Plasma cell dyscrasia-associated amyloidosis
The therapeutic domain includes amyloid-directed therapy alongside treatment of the underlying plasma cell disorder and related cardiac complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.